IGF-1 LR3

What is IGF-1 LR3?

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic, modified analog of human insulin-like growth factor 1 (IGF-1). The "Long R3" designation refers to two key structural modifications: an arginine substitution at the third position of the amino acid sequence and the addition of a 13-amino-acid extension peptide at the N-terminus. These modifications result in a dramatically extended biological half-life of approximately 20 to 30 hours compared to the approximately 12 to 15 minutes of unbound native IGF-1, while maintaining full biological activity at the IGF-1 receptor.

The extended half-life of IGF-1 LR3 is primarily due to its significantly reduced binding affinity for IGF binding proteins (IGFBPs), which normally regulate IGF-1 bioavailability by sequestering the peptide in circulation. Because IGF-1 LR3 evades IGFBP binding, a much larger fraction remains in its free, bioactive state, resulting in prolonged and potent IGF-1 receptor activation throughout the body. This makes it fundamentally different from IGF-1 DES, which also avoids binding proteins but has a much shorter half-life.

IGF-1 LR3 was originally developed as a research tool for studying IGF-1 signaling pathways and was widely used in cell culture media as a growth factor supplement. It is not FDA-approved for any clinical indication in humans and is classified as a research peptide. The compound has attracted significant attention in the research community due to its potent anabolic and mitogenic properties, with studies exploring its effects on muscle growth, recovery, metabolism, and cellular proliferation.

Clinical Research & Evidence

Research on IGF-1 LR3 spans several decades, beginning with its development as a tool for in vitro cell culture. The compound gained prominence when researchers at the Cooperative Research Centre for Tissue Growth and Repair in Australia characterized its pharmacological properties and demonstrated its enhanced potency relative to native IGF-1. Studies showed that IGF-1 LR3 was approximately 2 to 3 times more potent than native IGF-1 in stimulating cell proliferation in culture systems.

Animal studies have provided the most substantial evidence base for IGF-1 LR3's biological effects. Research in rodent models has demonstrated that systemic administration of IGF-1 LR3 may promote increases in lean body mass, enhance nitrogen retention, and support muscle protein synthesis. Studies by Tomas et al. showed that IGF-1 LR3 administration in rats resulted in significant increases in body weight and organ mass, with particularly notable effects on skeletal muscle tissue, suggesting potent anabolic activity.

Research has also explored the compound's effects on muscle regeneration and recovery. Studies in animal models of muscle injury indicate that IGF-1 pathway activation through analogs like LR3 may accelerate the recovery process by promoting satellite cell activation, myoblast differentiation, and protein accretion. These findings have generated interest in the potential therapeutic applications for muscle-wasting conditions, though human clinical trials for such indications have not been conducted with IGF-1 LR3 specifically.

The majority of published literature on IGF-1 LR3 consists of preclinical studies, in vitro experiments, and pharmacological characterization work. Controlled human clinical trials are limited, and the evidence base for effects in humans relies heavily on extrapolation from animal data and the broader IGF-1 research literature. Researchers emphasize the need for rigorous human studies to fully characterize the compound's safety and efficacy profile.

Potential Benefits

• Muscle hyperplasia potential: Research suggests IGF-1 LR3 may promote the formation of new muscle fibers (hyperplasia) in addition to enlarging existing fibers (hypertrophy), a property not commonly seen with other anabolic compounds.
• Enhanced recovery: Animal studies indicate that IGF-1 pathway activation may accelerate muscle recovery following exercise or injury by promoting satellite cell activation and protein synthesis.
• Increased protein synthesis: IGF-1 LR3 activates the PI3K/Akt/mTOR signaling pathway, which is central to muscle protein synthesis and cellular growth.
• Long-acting systemic effects: With a half-life of 20-30 hours, a single daily administration may provide sustained IGF-1 receptor activation throughout the body.
• Improved nutrient partitioning: Research suggests that IGF-1 signaling may promote preferential nutrient uptake by muscle tissue while reducing fat storage.
• Anti-catabolic properties: IGF-1 pathway activation may help preserve lean tissue during caloric restriction or periods of physiological stress.
• Connective tissue support: Some studies suggest IGF-1 may support collagen synthesis and connective tissue integrity, potentially benefiting joint and tendon health.
• Metabolic effects: IGF-1 signaling may enhance glucose uptake by skeletal muscle and influence lipid metabolism, potentially supporting body composition goals.

Dosing Protocol

IGF-1 LR3 is a research peptide without FDA-approved dosing guidelines. The protocols above are based on published research and commonly referenced ranges. Due to its long half-life, once-daily dosing is generally considered sufficient. Some researchers start at the lower end of the range and gradually increase based on tolerance and response. Cycling on and off is recommended to prevent receptor desensitization and to allow endogenous IGF-1 signaling to normalize. Always work with a qualified healthcare provider.

Reconstitution Guide

IGF-1 LR3 is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use. Use bacteriostatic water (BAC water) for multi-dose vials. Maintain strict aseptic technique throughout the process.

Step-by-step instructions: (1) Wipe both the peptide vial stopper and BAC water vial with alcohol swabs. (2) Draw the desired volume of BAC water into an insulin syringe. (3) Inject the water slowly along the inner wall of the vial, allowing it to drip gently onto the lyophilized powder. Do not spray directly onto the cake. (4) Gently swirl the vial until the powder is fully dissolved. Do not shake vigorously, as this may denature the peptide. (5) Once reconstituted, store refrigerated at 2-8 degrees Celsius and use within 14 days.

Half-Life & Pharmacokinetics

IGF-1 LR3 has an extended biological half-life of approximately 20 to 30 hours, which represents a dramatic improvement over native IGF-1 (approximately 12-15 minutes when unbound, or 12-15 hours when complexed with IGFBPs). The prolonged half-life results from the structural modifications that reduce IGFBP binding by approximately 100-fold, keeping the peptide in its free, bioactive form for an extended period.

Following subcutaneous injection, IGF-1 LR3 is absorbed into systemic circulation and distributes throughout the body. Unlike IGF-1 DES, which has primarily localized effects due to its rapid clearance, IGF-1 LR3 exerts systemic effects across multiple tissues. The compound activates IGF-1 receptors in skeletal muscle, liver, bone, and other tissues for the duration of its extended half-life. Elimination occurs through proteolytic metabolism and renal clearance. The prolonged pharmacokinetic profile supports once-daily dosing and provides relatively stable receptor activation over a 24-hour period.

Administration & Injection Sites

IGF-1 LR3 is administered via subcutaneous or intramuscular injection. Because of its long half-life and systemic distribution, the injection site is less critical than with short-acting compounds like IGF-1 DES. Subcutaneous injection is the most common route and is simpler for self-administration.

Use an insulin syringe with a 29-31 gauge needle for subcutaneous injections. For intramuscular injection, a 25-27 gauge needle of appropriate length may be used. Administer at a consistent time each day to maintain stable levels. Some protocols suggest post-workout administration to coincide with the anabolic window.

• Abdomen: Preferred subcutaneous site, inject 1-2 inches from the navel
• Thigh: Outer upper thigh, suitable for subcutaneous or intramuscular injection
• Upper arm: Posterior triceps area for subcutaneous injection
• Deltoid: For intramuscular injection, if preferred

Rotate injection sites regularly to prevent localized tissue reactions, lipodystrophy, or scar tissue formation. Always clean the injection site with an alcohol swab before injecting and allow it to dry completely. Dispose of used syringes in a sharps container.

Side Effects & Safety

The side effect profile of IGF-1 LR3 is informed by both IGF-1 pathway pharmacology and available preclinical data. As with all IGF-1 analogs, the compound's growth-promoting properties carry both potential benefits and risks.

Common Side Effects

• Hypoglycemia (common): IGF-1 receptor activation can lower blood glucose, potentially causing lightheadedness, shakiness, or sweating. More pronounced in fasted states.
• Injection site reactions (common): Redness, soreness, or mild swelling at the injection site.
• Water retention (common): Mild to moderate fluid retention, particularly in the hands and feet, has been reported with IGF-1 pathway compounds.

Uncommon Side Effects

• Joint pain (uncommon): Arthralgia may develop with sustained elevated IGF-1 activity.
• Headache (uncommon): Mild to moderate headaches have been associated with IGF-1 signaling compounds.
• Jaw or facial changes (uncommon): Prolonged elevated IGF-1 may contribute to soft tissue growth in extremities and facial features.
• Gut distension (uncommon): Chronic elevated IGF-1 may promote visceral organ growth with long-term use.

Rare/Theoretical Concerns

• Cell proliferation risk (theoretical): Sustained IGF-1 receptor activation is a known mitogenic signal, raising theoretical concerns about promoting unwanted cell growth over prolonged periods.
• Organ enlargement (rare): Chronic supraphysiological IGF-1 activity may contribute to organomegaly with extended high-dose use.

Stacking & Interactions

IGF-1 LR3 is sometimes used in conjunction with other growth-related compounds in research protocols. Understanding how it interacts with other compounds is essential for safety.

The most significant interaction concern is with insulin and other glucose-lowering compounds. IGF-1 LR3 can cause hypoglycemia on its own, and combining it with exogenous insulin dramatically increases this risk. Always have glucose tabs or fast-acting carbohydrates available when using any IGF-1 analog.

Storage & Handling

In lyophilized form, IGF-1 LR3 should be stored at -20 degrees Celsius (freezer temperature) for optimal long-term stability. Under these conditions, the powder typically remains stable for 12 to 24 months. For shorter-term storage of up to several weeks, refrigeration at 2-8 degrees Celsius is acceptable. Protect the vial from light and moisture at all times.

Once reconstituted with bacteriostatic water, the solution should be stored in the refrigerator at 2-8 degrees Celsius and used within 14 days. The preservative in bacteriostatic water helps prevent microbial contamination during this period. If reconstituted with sterile water (no preservative), the solution should be used within 48 hours.

Do not freeze reconstituted solutions, as ice crystal formation can damage the peptide structure. Avoid repeated temperature fluctuations and do not leave reconstituted vials at room temperature for extended periods. For travel, transport lyophilized powder in an insulated bag with ice packs and reconstitute upon arrival.

Signs of degradation: The reconstituted solution should be clear and colorless. Discard if it appears cloudy, contains visible particles, develops a yellowish tint, or has an unusual odor.

Legal & Regulatory Status

IGF-1 LR3 is not FDA-approved for any clinical use in humans. It is marketed and sold as a research chemical under designations such as "for research use only" or "not for human consumption." It is not a controlled substance under the United States Controlled Substances Act, but it is regulated differently from approved pharmaceutical products.

The compound is explicitly prohibited by the World Anti-Doping Agency (WADA) under the S2 category of peptide hormones, growth factors, related substances, and mimetics. Use of IGF-1 LR3 by athletes subject to anti-doping testing constitutes a violation. It is similarly banned by the International Olympic Committee (IOC), NFL, MLB, NCAA, and virtually all major professional and amateur sports organizations.

Note that while recombinant human IGF-1 (mecasermin, brand name Increlex) is FDA-approved for the treatment of severe primary IGF-1 deficiency, IGF-1 LR3 is a distinct modified analog that has not undergone the regulatory approval process. Regulatory status for research peptides varies by country, and individuals should verify applicable laws in their jurisdiction.

Recommended Bloodwork & Monitoring

Due to the potent systemic effects of IGF-1 LR3 on glucose metabolism, growth signaling, and organ function, comprehensive monitoring is recommended for anyone using this compound under medical supervision.

Before Starting

• IGF-1 serum level: Establish baseline to track changes and assess systemic impact
• Fasting blood glucose and HbA1c: Critical baseline given hypoglycemia risk
• Fasting insulin level: Evaluate insulin sensitivity and metabolic status
• Complete metabolic panel (CMP): Liver and kidney function, electrolytes
• Complete blood count (CBC): Baseline hematologic values
• Thyroid panel (TSH, Free T3, Free T4): Growth hormone and IGF-1 can influence thyroid function

During Use (every 4-6 weeks)

• IGF-1 serum level: Monitor to ensure levels do not become excessively supraphysiological
• Fasting blood glucose: Regular monitoring; daily finger-stick checks recommended
• Liver function tests: ALT, AST to monitor hepatic response
• Kidney function: BUN, creatinine to assess renal status
• Lipid panel: IGF-1 may influence lipid metabolism

Frequently Asked Questions

Related Compounds